EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fulgent Genetics's enterprise value is $358.8 Mil.
Fulgent Genetics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-46.3 Mil. Therefore, Fulgent Genetics's EV-to-EBITDA for today is -7.74.
The historical rank and industry rank for Fulgent Genetics's EV-to-EBITDA or its related term are showing as below:
FLGT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -170.44 Med: 2.06 Max: 270.18
Current: -7.74
During the past 10 years, the highest EV-to-EBITDA of Fulgent Genetics was 270.18. The lowest was -170.44. And the median was 2.06.
FLGT's EV-to-EBITDA is ranked worse than 100% of 116
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.51
vs FLGT: -7.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Fulgent Genetics EV-to-EBITDA Historical Data
The historical data trend for Fulgent Genetics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fulgent Genetics's EV-to-EBITDA
For the Diagnostics & Research subindustry, Fulgent Genetics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's EV-to-EBITDA falls into.
Fulgent Genetics's current Enterprise Value is $358.8 Mil.
Fulgent Genetics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Fulgent Genetics's PE Ratio for today is calculated as:
Fulgent Genetics's share price for today is $21.75.
Fulgent Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Fulgent Genetics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Fulgent Genetics (Fulgent Genetics) Business Description
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FLGT has been successfully added to your 